DNA-Encoded Library Data: Unlocking Chemomic Insights for Drug Discovery

DNA-encoded library (DEL) screening has become a standard tool in small-molecule drug discovery. Yet, even as its adoption for hit finding grows, the vast amounts of data it generates are generally overlooked. More than 99% of the information produced during a DEL screen is typically neglected in favor of choosing a handful of hits to synthesize and test. That ignored data holds incredible, untapped insight into molecular interactions, structure–activity relationship (SAR) trends, mechanism of action (MOA) and potential risks that can radically influence compound progression.

This webinar will explore chemonics, a framework for unlocking the full power of DEL data. Built on a highly validated DEL platform and enhanced by computational sciences, this approach will shift how discovery teams approach early-phase decision-making and will transform raw screening output into structured, decision-ready insight before synthesis even begins.

The featured speakers will explore how chemomics works, why it matters and how it changes the economics and efficiency of small molecule discovery. Rather than relying on a narrow set of enriched binders, chemomic analysis entails full-selection data to identify meaningful SAR patterns, visualize structure–function relationships and guide discovery programs with clarity from the outset — all before synthesis begins.

Attendees will gain a deep understanding of how chemomic approaches deliver mechanistic insight across multiple chemical series, dramatically improving the starting point for hit-to-lead efforts. Beyond guiding better hit selection, chemomics integrates iterative feedback from hit synthesis and validation to refine SAR hypotheses and generate new, higher-potential compound suggestions. This enables dynamic optimization of lead series, not just selecting better starting points, but actively evolving them. This session will highlight the value of early data-driven triage and how a more complete picture of the DEL landscape helps avoid costly downstream surprises.

This is not just a technology update. It is a new mindset for discovery. Chemomic approaches represent a departure from conventional screening and hit validation models. By applying comprehensive DEL data to work earlier, discovery programs can be front-loaded with years of SAR for multiple MOAs, allowing researchers to make more confident decisions, reduce program risk and unlock candidates with greater therapeutic potential.

Whether experienced as a DEL practitioner or exploring how to improve hit program efficiency, this session will offer a forward-looking perspective on what discovery should look like in the data-driven era.

Register for this webinar to learn how DNA-encoded library data can be harnessed through chemomics to accelerate and refine small molecule discovery.

Speakers

Matt Clark, PhD, Chief Scientific Officer, X-Chem

Matt Clark is X-Chem’s Chief Scientific Officer and a globally recognized leader in DNA-encoded library (DEL) technology. As a founding team member, Matt has played a central role in transforming X-Chem from a niche chemistry platform into a world-leading drug discovery engine serving the biopharma industry. His scientific leadership has shaped the development of next-generation DEL approaches and expanded the reach of the platform across diverse target classes.

Before his CSO role, Matt served as X-Chem’s VP of Chemistry and SVP of Research. He has authored key publications in the DEL field and holds numerous patents. Matt earned his PhD in Chemistry from Cornell University, completed postdoctoral studies at MIT and holds a BS in Biochemistry from UC San Diego.

Message Presenter

Erin Davis, PhD, Chief Technology Officer, X-Chem

Erin Davis is the Chief Technology Officer at X-Chem, where she leads the development of a fully integrated discovery platform that brings together DEL, medicinal chemistry, computational modeling and machine learning to power smarter, faster preclinical discovery. A leader at the intersection of science and technology, Erin brings deep expertise in building informatics platforms that scale across pharma and biotech. Prior to joining X-Chem, she drove the growth of Schrödinger’s LiveDesign platform and founded their discovery informatics team.

Erin holds a PhD in Computational Chemistry from the University of Montana.

Message Presenter